论文部分内容阅读
目的探讨血清IL-18和IL-10在肝细胞肝癌(HCC)患者中的变化及其意义。方法采用ELISA法检测65例HCC患者(HCC组)血清IL-18和IL-10水平,并与正常对照组比较。分析HCC患者合并肝硬化(LC)与合并慢性乙型肝炎(CHB)间血清IL-18、IL-10水平的差异。结果HCC组血清IL-18、IL-10水平明显均高于正常对照组(P<0.05);HCC合并LC患者血清IL-18水平明显高于合并CHB患者(P<0.05),而两者间血清IL-10无统计学差异(P>0.05)。结论 HCC患者体内以Th2型免疫反应为主,其血清IL-18、IL-10的水平同时升高可以抑制机体的免疫功能。
Objective To investigate the changes of serum IL-18 and IL-10 in patients with hepatocellular carcinoma (HCC) and its significance. Methods Serum levels of IL-18 and IL-10 in 65 HCC patients (HCC group) were detected by ELISA, and compared with the normal control group. To analyze the difference of serum IL-18 and IL-10 levels between HCC patients with cirrhosis (LC) and chronic hepatitis B (CHB). Results The levels of serum IL-18 and IL-10 in HCC group were significantly higher than those in normal control group (P <0.05). The levels of serum IL-18 in HCC with LC were significantly higher than those in CHB group (P <0.05) Serum IL-10 was no significant difference (P> 0.05). Conclusions The Th2 type immune response is the major component of HCC patients. The serum IL-18 and IL-10 level can be simultaneously increased to suppress the immune function.